Usability of an educational intervention to overcome therapeutic inertia in multiple sclerosis care by Saposnik, Gustavo et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Usability of an educational intervention to overcome therapeutic inertia in
multiple sclerosis care
Saposnik, Gustavo; Tobler, Philippe N; Caceres, Fernando; Terzaghi, Maria A; Ruff, Christian C;
Maurino, Jorge; Fruns Quintana, Manuel; Oh, Jiwon; Montalban, Xavier; Mamdani, Muhammad
Abstract: Background: Educational interventions are needed to overcome knowledge-to-action gaps in
clinical care. We previously tested the feasibility and potential efficacy of an educational intervention
that facilitates treatment decisions in multiple sclerosis care. A demonstration of the usability of such
an intervention is crucial prior to demonstration of efficacy in a large trial. Objectives: To evaluate the
usability of a novel, pilot-tested intervention aimed at neurologists to improve therapeutic decisions in
multiple sclerosis (MS) care. Methods: We surveyed 50 neurologists from Chile, Argentina, and Canada
randomized to an educational intervention arm of a pilot feasibility study using the System Usability Score
(SUS) to assess the usability of a traffic light system (TLS)-based educational intervention. The TLS
facilitates therapeutic decisions, allowing participants to easily recognize high-risk scenarios requiring
treatment escalation. The SUS is a validated 10-item questionnaire with five response options. The
primary outcome was the average and 95% confidence interval (CI) of the SUS score. Values above 68 are
considered highly usable. Results: Of 50 neurologists invited to be part of the study, all completed the
SUS scale and the study. For the primary outcome, the average usability score was 74.7 (95%CI 70.1–
79.2). There was one outlier with a score of 35. The usability score excluding the outlier was 76.8 (95%CI
72.7–80.8). Multivariate analysis revealed no association between participants’ characteristics and the
SUS score. Conclusions: Our educational intervention has shown high usability among neurologists. The
next step is to evaluate the effectiveness of this educational intervention in facilitating treatment decisions
for the management of multiple sclerosis in a large trial.
DOI: https://doi.org/10.3389/fneur.2018.00522
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153364
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Saposnik, Gustavo; Tobler, Philippe N; Caceres, Fernando; Terzaghi, Maria A; Ruff, Christian C; Mau-
rino, Jorge; Fruns Quintana, Manuel; Oh, Jiwon; Montalban, Xavier; Mamdani, Muhammad (2018).
Usability of an educational intervention to overcome therapeutic inertia in multiple sclerosis care. Fron-
tiers in Neurology, 9:1-7.
DOI: https://doi.org/10.3389/fneur.2018.00522
2
ORIGINAL RESEARCH
published: 10 July 2018
doi: 10.3389/fneur.2018.00522
Frontiers in Neurology | www.frontiersin.org 1 July 2018 | Volume 9 | Article 522
Edited by:
Jorge Matias-Guiu,
Complutense University of Madrid,
Spain
Reviewed by:
Julián Benito León,
Hospital Universitario 12 De Octubre,
Spain
Juan Ignacio Rojas,
Hospital Italiano de Buenos Aires,
Argentina
*Correspondence:
Gustavo Saposnik
saposnikg@smh.ca
Specialty section:
This article was submitted to
Multiple Sclerosis and
Neuroimmunology,
a section of the journal
Frontiers in Neurology
Received: 19 May 2018
Accepted: 13 June 2018
Published: 10 July 2018
Citation:
Saposnik G, Tobler PN, Caceres F,
Terzaghi MA, Ruff C, Maurino J,
Fruns Quintana M, Oh J, Montalban X
and Mamdani M (2018) Usability of an
Educational Intervention to Overcome
Therapeutic Inertia in Multiple
Sclerosis Care. Front. Neurol. 9:522.
doi: 10.3389/fneur.2018.00522
Usability of an Educational
Intervention to Overcome
Therapeutic Inertia in Multiple
Sclerosis Care
Gustavo Saposnik 1,2,3*, Philippe N. Tobler 2, Fernando Caceres 4, Maria A. Terzaghi 1,3,
Christian Ruff 2, Jorge Maurino 5, Manuel Fruns Quintana 6, Jiwon Oh 1, Xavier Montalban 1,7
and Muhammad Mamdani 8
1Department of Medicine, Division of Neurology, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada,
2 Laboratory for Social and Neural Systems Research, Department of Economics, University of Zurich, Zurich, Switzerland,
3Decision Neuroscience Unit, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Toronto, ON,
Canada, 4Department of Neurology, Instituto de Neurociencias Buenos Aires, Buenos Aires, Argentina, 5Neuroscience Area,
Medical Department, Roche Farma, Madrid, Spain, 6Clinica Las Condes, Santiago, Chile, 7Neurology-Neuroimmunology
Department and Neurorehabilitation Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Barcelona, Spain, 8Healthcare
Analytics Research, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
Background: Educational interventions are needed to overcome knowledge-to-action
gaps in clinical care. We previously tested the feasibility and potential efficacy of an
educational intervention that facilitates treatment decisions in multiple sclerosis care. A
demonstration of the usability of such an intervention is crucial prior to demonstration of
efficacy in a large trial.
Objectives: To evaluate the usability of a novel, pilot-tested intervention aimed at
neurologists to improve therapeutic decisions in multiple sclerosis (MS) care.
Methods: We surveyed 50 neurologists from Chile, Argentina, and Canada randomized
to an educational intervention arm of a pilot feasibility study using the System Usability
Score (SUS) to assess the usability of a traffic light system (TLS)-based educational
intervention. The TLS facilitates therapeutic decisions, allowing participants to easily
recognize high-risk scenarios requiring treatment escalation. The SUS is a validated 10-
item questionnaire with five response options. The primary outcome was the average and
95% confidence interval (CI) of the SUS score. Values above 68 are considered highly
usable.
Results: Of 50 neurologists invited to be part of the study, all completed the SUS scale
and the study. For the primary outcome, the average usability score was 74.7 (95%CI
70.1–79.2). There was one outlier with a score of 35. The usability score excluding
the outlier was 76.8 (95%CI 72.7–80.8). Multivariate analysis revealed no association
between participants’ characteristics and the SUS score.
Conclusions: Our educational intervention has shown high usability among
neurologists. The next step is to evaluate the effectiveness of this educational intervention
in facilitating treatment decisions for the management of multiple sclerosis in a large trial.
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BACKGROUND
Recent studies have shown many patients with multiple sclerosis
(MS) remain undertreated (1, 2). Therapeutic inertia (TI) is
defined as the lack of treatment initiation or escalation when
treatment goals are unmet (3, 4). Approximately 70–80% of
neurologists caring for patients with MS are estimated to be
affected by TI (2). Physician factors are most commonly related
to TI (e.g., low tolerance to uncertainty, status quo bias) (5, 6).
Educational strategies are developed in medicine to either fill
knowledge gaps (where there is limited background information
on the management of a medical condition) or knowledge-to-
action gaps (i.e., failure to integrate background knowledge into a
diagnostic or therapeutic decision). To the best of our knowledge,
there are no such interventions aimed at influencing clinician
decisions to ameliorate the consequences of TI (e.g., poor patient
outcomes) (2–4). In a previous study, we showed the feasibility
and potential efficacy of an educational intervention using a
traffic light system (TLS) to overcome TI in the management of
MS (7). The TLS emerged as a warning and risk categorization
strategy to reduce human errors (8). It facilitates the decision-
making process relying on a “hard wired” process that applies
the traffic light colors to match three types of situations: red light
(“high risk”/“stop and think”), yellow light (“warning”/“reassess
in a period of time”) and green light (“stable”/“continue the same
strategy”).
The TLS aids the integration of specific situations with an
action (9, 10). For example, studies have shown that the TLS can
help physicians select the course of action for children presenting
with fever or facilitate healthier choices by signaling with a red
color food with high content of sugar, cholesterol, and sodium
(11). However, many educational interventions or scores are not
widely used or implemented in clinical practice. Consequently, it
is crucial to determine the potential usability of an educational
intervention prior to testing its efficacy in large and expensive
randomized clinical trials.
In the present study, we evaluated the usability of our
educational intervention among neurologists caring for MS
patients. We hypothesized that our educational intervention
using the TLS has high usability, as defined by the system usability
score (SUS), in this population.
METHODS
We included neurologists participating in an international
(Chile, Argentina, Canada), parallel-group, randomized pilot
study evaluating the feasibility of the educational intervention
(TLS: active group) (Figure 1) compared to usual care (control
group) in the management of MS (7). The recruitment of
participants was facilitated by the National Neurological Societies
(MS Society for Canada) of the three participating countries
providing mailing lists of non-specialized neurologists and those
with MS expertise. Participants randomized to the educational
intervention were exposed to 10 case-scenarios and asked to
make a therapeutic choice, guided by the TLS-based education
intervention. Following these case-scenarios, they were asked to
assess the utility of the TLS using the SUS. Given our previous
findings (e.g., association between physicians’ risk preferences
and aversion to ambiguity with TI), we also included previously
tested experiments to assess participants’ risk preferences and
aversion to ambiguity to evaluate their association with the
SUS (2). In brief, participants were asked about the minimal
certain payoff they would prefer over the equiprobable gamble
of winning 400 or 0 US$ (expected value of 200 US$). Ambiguity
aversion is defined as dislike for events with unknown probability
over events with known probability. Participants had to choose
between two options: (a) a 50% chance of winning 400 vs. 0
US$ or (b) an unknown probability of winning 400 US$ (where
the unknown probability of winning may be higher or lower
than 50%). Further details of the protocol were published in
ClinicalTrials.gov # NCT03134794 and elsewhere (2, 7).
The System Usability Score (SUS)
The SUS is a validated 10-item questionnaire with a 5-point
Likert rating scale that ranges from 1 = strongly disagree to 5 =
strongly agree. Questions with positive and negative connotation
are alternated to avoid any biases. A score is calculated by
subtracting participants’ responses from 5 for even questions and
by subtracting one from responders’ answers for odd questions.
This procedure scales all values from 0 to 4 (with four being the
most positive response). The final score is obtained by adding
the converted responses for each participant and multiplying the
total by 2.5. As a result, the possible values range from 0 to 100
(12). A score of 68 or higher is considered “highly acceptable”
(13–16). The SUS has been validated in different populations and
countries and used in over 500 instruments (13–16).
Educational Intervention (Figure 1): The
TLS
Our educational intervention is based on the application of
the TLS to medical-decision making (9, 10, 17). The TLS was
intended to assist participants in identifying high-risk case-
scenarios, where MS patients had both clinical relapses and
evidence of radiological activity. Our educational intervention
focused on MS because of tiered therapeutic options and
consensus about treatment escalation (e.g., presence of clinical
relapses and radiological activity) (18, 19). Our educational
intervention was delivered in a single presentation. The total
duration of the educational intervention was <5min (Figure 1)
(7).
Participants were asked to select the traffic light that best
matched the case-scenario based on clinical relapse history and
results from brain imaging. For example, a “red” traffic light may
have been selected for a patient who had both a clinical relapse
and some level of activity in brain imaging (Figure 2), where
treatment escalation is likely the correct decision. Similarly,
participants may have selected the color “yellow” (representing
caution requiring a reassessment within 6–12 months) when
case-scenarios had either a clinical relapse or some degree of
activity in brain imaging (but not both). At the end of the study,
participants were asked to evaluate the delivered educational
intervention using the validated SUS instrument. Further details
were published in the pilot study (7).
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FIGURE 1 | continued.
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FIGURE 1 | Educational intervention: the traffic light system may facilitate therapeutic decisions in MS care (7). Participants viewed the two informative panels (A,B)
and a third panel providing an example (C). (A) Introduction of the traffic light system. (B) Implementation of the traffic light system. (C) Example application of the
traffic light system.
Treatment Options
The treatment options for relapsing-remitting MS (RRMS)
include first-line (beta interferons, glatiramer acetate,
etc.), second-line (fingolimod), and third-line (natalizumab,
alemtuzumab) therapies (20). Other recently approved agents
were not included if they were not available in the participating
countries at the time of the study (e.g., Ocrelizumab, Cladribine,
etc.). For the present analysis, we used the aforementioned
scheme according to the current clinical practice (2, 21, 22).
Outcome Measures
The primary outcome was the average SUS. Values >68 points
are considered to reflect high usability (13, 14). The secondary
outcome was the proportion of participants with a usability score
>68 points.
Statistical Analysis
Given the pilot nature of this study, we performed primarily
descriptive statistics for the primary and secondary outcomes.
As a secondary analysis, we developed a linear regression model
to explore factors associated with the usability score including
age, gender, general neurologist vs. MS specialist status, years
of experience, practice setting and volume, physicians’ risk
preferences and aversion to ambiguity, and authorship in a
recent peer-review publication. Variables entered into the models
were defined a priori based on the results of our previous
studies (e.g., MS specialist vs. general neurologists, physicians’
risk preferences and aversion to ambiguity) adjusted for age and
sex (7). Specialist status was self-defined. Collinearity among
variables was explored by variance inflation factors (VIFs). Values
below 10 are considered a good indicator of lack of collinearity.
All tests were 2-tailed, and p < 0.05 was considered significant.
We used STATA 13 (College Station, TX: StataCorp LP) to
conduct all analyses.
The study was approved by the Research Ethics Board of St.
Michael’s Hospital, University of Toronto, Canada.
RESULTS
Of 50 neurologists who were invited to participate in the study,
all (100%) completed the usability scale. Overall, the mean (SD)
age was 45.6 (± 11.1) years; 21 (42%) were female neurologists.
One third of participants primarily focused their practice on MS
care. Table 1 summarizes baseline characteristics of the study
population.
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FIGURE 2 | Usability Score System. The SUS is a 10 point-item questionnaire
with 5 response options.
For the primary outcome, the average usability score [95%
confidence intervals (CI)] was 74.7 (95%CI 70.1–79.2). There was
one outlier with a score of 35. The usability score excluding that
outlier was 76.8 (72.7–80.8).
For the secondary outcome, 70% (n = 35) of participants
achieved a usability score >68 points. SUS percentiles are shown
in Figure 3.
TABLE 1 | Baseline characteristics of participants.
Characteristics Total n = 50
AGE
Years (mean ± SD) 45.6 ± 11.1
SEX
Female 21 (42.0)
SPECIALTY
MS specialists 18 (36.0)
General neurologists who care for MS patients 32 (64.0)
PRACTICE SETTING
Academic 21 (42.0)
Community or private institution 29 (58.0)
% TIME IN CLINICAL PRACTICE
50–75% 18 (36.0)
Greater than 75% 25 (50.0)
YEARS IN PRACTICE
mean (±SD) 19.0 ± 11.0
SEEN MORE THAN 20MS PATIENTS PER MONTH 34 (68.0)
AUTHOR OF A PEER-REVIEWED PUBLICATION IN THE 23 (46.0)
LAST 12 MONTHS
Numbers in brackets indicate percentages.
FIGURE 3 | Percentiles of the Usability Score System (SUS).
Multivariate regression analysis revealed no statistically
significant association between the variables tested and SUS score
(Table 2). There was no collinearity among the included variables
as reflected by VIF scores < 1.5. Overall, the included variables
only explained <9% of the variability of the SUS scores (r2 =
0.088).
DISCUSSION
In the present study, we found a high level of usability of a
TLS-based educational intervention aimed at overcoming TI in
the management of MS. Our results suggest that a TLS-based
intervention is amenable to being widely used in clinical practice.
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TABLE 2 | Multivariate analysis: factors associated with the SUS score.
Variable Coefficient Standard error 95%CI VIF
Age, in years 0.13 0.22 −0.031 0.58 1.15
Sex 0.50 4.86 −9.30 10.3 1.11
MS specialist (vs. general neurologist) −6.74 4.84 −16.5 3.02 1.02
Risk preference, in US$ 0.014 0.03 −0.04 0.06 1.24
Aversion to ambiguity −5.44 4.72 −15.0 4.08 1.02
Constant 70.1 10.5 48.8 91.3 NA
Number of observations: 50; r2 = 0.088; NA, not applicable. VIF, Variance inflation factors. Values <10 are considered as evidence for lack of collinearity.
We identified no specific factors associated with higher usability
scores, suggesting that its use may not be affected by age, gender,
expertise, years of practice, volume of MS patients seen per week
or practice setting. The usability of the TLS was not influenced by
individual physicians’ risk preferences or aversion to ambiguity.
The use of the TLS is a novel way to optimize treatment
decisions. It has been successfully applied to different medical
fields, including the selection of healthier food choices leading
to weight loss or the detection of children with fever at high
risk of developing a serious bacterial infection (9, 10). In a
previous randomized trial, we pilot-tested the application of the
TLS to determine the feasibility (and preliminary efficacy data for
sample size calculation for a larger trial) in treatment decisions in
MS care.We showed feasibility and promising results in reducing
TI (OR 0.57; 95% CI 0.26–1.22) (7).
Our findings have practical clinical implications. Our
results showed excellent usability scores for a simple and
brief educational intervention that helps categorize MS
patients according to their future risk of disease progression.
This educational strategy was designed to ameliorate TI by
overcoming knowledge-to-action gaps. Physicians who are
resistant to treatment changes (e.g., status quo) when indicated
by best practice guidelines may benefit from using the TLS.
Our results nicely integrate with our previous work showing
one of the major components influencing TI is aversion to risk
and ambiguity (defined as the probability of an event being
unknown) (2, 7). To the best of our knowledge, there are no other
proven educational interventions to address this phenomenon.
Aversion to risk and ambiguity are concepts derived from studies
in behavioral economics to characterize individuals and describe
their decisions. We previously showed that aversion to ambiguity
is an independent predictor of physicians’ TI (2). The use of the
TLS may help such participants to make prompt decisions and
overcome TI.
Our study has some limitations. First, the sample size is small
given the pilot design. Second, we used a single measurement of
usability. However, the SUS has been validated and extensively
applied to over 500 interventions (13–15). Finally, we included
participants from three specific countries. It is possible that
these findings may not be generalizable to clinicians from other
countries.
Despite these limitations, our study suggests that a simple and
brief educational intervention applying the TLS may have high
potential for use by neurologists when evaluating therapeutic
choices for MS patients. Our findings should be put into
perspective as the TLS may facilitate early identification of
high-risk patients that require a therapeutic change. For example,
clinicians may apply the TLS for patients waiting to be seen in
the outpatient clinics by adding a color tag to those screened as
high-risk according to the medical situation (“red color tag” for
MS patients with new symptoms suggestive of a clinical relapse
and radiological progression). This approach may help planning
resources, facilitate timely discussions and prioritized clinical
outcomes when treatment escalation is indicated (23). Although
our intervention was designed to facilitate therapeutic decisions
in MS care, it can be applied to decisions in other neurological
fields (e.g., epilepsy, migraine) and chronic conditions (e.g.,
hypertension, diabetes). Given that we have tested the feasibility
and usability of this promising educational intervention, the next
step is the assessment of its efficacy in affecting management
decisions and resultant clinical outcomes in a large, properly
designed randomized clinical trial.
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